Various regulatory authorities like ICH, USFDA, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in Active Pharmaceutical Ingredient's (API's). Qualification of the impurities is the process of acquiring and evaluating data that establishes biological safety of an individual impurity; thus, revealing the need and scope of impurity profiling of drugs in pharmaceutical research. Identification of impurities is done by variety of Chromatographic and Spectroscopic techniques, either alone or in combination with other techniques. There are different methods for detecting and characterizing impurities with TLC, HPLC, HPTLC, AAS etc. Conventional
Introduction
There is an ever increasing interest in impurities present in API's. Recently, not only purity profile but also impurity profile has become essential as per various regulatory requirements. In the pharmaceutical world, an impurity is considered as any other organic material, besides the drug substance, or ingredients, arise out of synthesis or unwanted chemicals that remains with API's. The impurity may be developed either during formulation, or upon aging of both API's and formulated API's in medicines. A good illustration of this definition may be identification of impurity in API's like 1-(1, 2, 3, 5, 6, 7-hexahydro-s-indacen-4-yl)-3-4[-1-hydroxy-1-methyl-ethyl)-furan-2-sulphonylurea using Multidisciplinary approach [1] . The presence of these unwanted chemicals, even in small amount, may influence the efficacy and safety of the pharmaceutical products. Impurity profiling (i.e., the identity as well as the quantity of impurity in the pharmaceuticals), is now gaining critical attention from regulatory authorities.
The different Pharmacopoeias, such as the British Pharmacopoeia (BP), United States Pharmacopeia (USP), and Indian Pharmacopoeia (IP) are slowly incorporating limits to allowable levels of impurities present in the API's or formulations.
The International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) has also published guidelines for validation of methods for analysing impurities in new drug substances, products, residual solvents and microbiological impurities [2] [3] [4] [5] .
A number of articles [8] [9] [10] have stated guidelines and designed approaches for isolation and identification of process-related impurities and degradation products, using Mass spectrometry (MS), Nuclear Magnetic Resonance (NMR), High Performance Liquid Chromatography (HPLC), Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS), and Tandem Mass Spectrometry for pharmaceutical substances.
Present article reveals different impurities found in the API's, methods for identifying them and the possible measures to deal with the interferences caused by them. Impurity profile is the description of identified and unidentified impurities present in new drug substances. Impurities can be described as shown in Table 1 In synthetic organic chemistry, getting a single end product with 100% yield is very rare;
there is always a chance of having by-products. In the case of paracetamol bulk, diacetylated paracetamol may be formed as a by-product.
Impurities can also be formed by degradation of the end product during manufacturing of propionic acid (PPPA) and 2-(4-n-butylphenyl) propionic acid (BPPA), which are reported to be well known impurities in IBP [12] . The degradation products of diclofenac-Na and clotrimazole [13] , paclitaxel [14] are also reported.
ICH limits for impurities
According to ICH guidelines on impurities in new drug products, identification of impurities below 0.1% level, is not considered to be necessary, unless potential impurities are expected to be unusually potent or toxic. According to ICH, the maximum daily dose qualification threshold to be considered is as follows;
< 2g/day 0.1 % or 1 mg per day intake (whichever is lower) >2g/day 0.05%
In summary, the new drug substance specifications should include, limits for-
i) Organic Impurities
Each specific identified impurity -Each specific unidentified impurity at or above 0.1% 
Crystallization-related impurities
Based on the realization that the nature of structure adopted by a given compound upon crystallization, could exert a profound effect on the solid-state properties of that system, the pharmaceutical industry is required to take a strong interest in polymorphism and solvatomorphism as per the regulations laid down by the regulatory authorities.
Polymorphism is the term used to indicate crystal system where substances can exist in different crystal packing arrangements, all of which have the same elemental composition.
Whereas, when the substance exists in different crystal packing arrangements, with a different elemental composition; the phenomenon is known as Solvatomorphism [6] .
Stereochemistry-related impurities
It is of paramount importance to look for stereochemistry related compounds; that is, those compounds that have similar chemical structure but different spatial orientation, these compounds can be considered as impurities in the API's. Chiral molecules are frequently called enantiomers. The single enantiomeric form of chiral drug is now considered as an improved chemical entity that may offer a better pharmacological profile and an increased therapeutic index with a more favourable adverse reaction profile. However, the pharmacokinetic profile of levofloxacin (S-isomeric form) and ofloxacin (R-isomeric form) are comparable, suggesting the lack of advantages of single isomer in this regard [15] . The prominent single isomer drugs, which are being marketed, include levofloxacin (S-ofloxacin), lavalbuterol (R-albuterol), and esomeprazole (S-omeprazole). dichloromethane, methanol and toluene with propionitrile as the internal standard [16] .
Synthetic intermediates and by-products
Impurities in pharmaceutical compounds or a new chemical entity (NCE) can originate during the synthetic process from raw materials, intermediates and/or by-products. For example, impurity profiling of ecstasy tablets by GC-MS [17] , and MDMA samples, produced impurities in intermediates via reductive amination route [18] .
Formulation-related impurities
Many impurities in a drug product can originate from excipients used to formulate a drug substance. In addition, a drug substance is subjected to a variety of conditions in the process of formulation that can cause its degradation or have other undesirable reactions. If the source is from an excipient, variability from lot to lot may make a marginal product, unacceptable for reliability. Solutions and suspensions are inherently prone to degradation due to hydrolysis or solvolysis [19] . Fluocinonide Topical Solution USP, 0.05%, in 60-mL bottles, was recalled in the United States because of degradation/impurities leading to sub-potency [20] . In general, liquid dosage forms are susceptible to both degradation and microbiological contamination. In this regard, water content, pH of the solution/suspension, compatibility of anions and cations, mutual interactions of ingredients, and the primary container are critical factors.
Microbiological growth resulting from the growth of bacteria, fungi, and yeast in a humid and warm environment may results in unsuitability of an oral liquid product for safe human consumption. Microbial contamination may occur during the shelf life and subsequent consumer-use of a multiple-dose product, either due to inappropriate use of certain preservatives in the preparations, or because of the semi-permeable nature of primary containers [21] .
Impurities arising during storage
A number of impurities can originate during storage or shipment of drug products. It is essential to carry out stability studies to predict, evaluate, and ensure drug product safety [6] .
Method related impurity
A known impurity, 1-(2, 6-dichlorophenyl) indolin-2-one is formed in the production of a parenteral dosage form of diclofenac sodium, if it is terminally sterilized by autoclave [22] . The conditions of the autoclave method (i.e., 123 + 2 o C) enforce the intramolecular cyclic reaction of diclofenac sodium forming an indolinone derivative and sodium hydroxide. The formation of this impurity has been found to depend on initial pH of the formulation. 
Mutual interaction amongst ingredients

Functional group-related typical degradation
Ester hydrolysis can be explained with a few drugs viz aspirin, benzocaine, cefotaxime, ethyl paraben [23] , and cefpodoxime proxetil [25] .
Hydrolysis is the common phenomenon for ester type of drugs, especially in liquid dosage forms viz benzylpenicillin, oxazepam and lincomycin.
Oxidative degradation of drugs like hydrocortisone, methotrexate, hydroxyl group directly bonded to an aromatic ring (viz phenol derivatives such as catecholamines and morphine), conjugated dienes (viz vitamin A and unsaturated free fatty acids), heterocyclic aromatic rings, nitroso and nitrite derivatives, and aldehydes (especially flavorings) are all susceptible to oxidative degradation.
In mazipredone, the hydrolytic and oxidative degredation pathway in 0.1 mol L -1 hydrochloric acid and sodium hydroxide at 80 0 C were studied [26] .
Photolytic cleavage includes example of pharmaceutical products that are exposed to light while being manufactured as solid or solution, packaged, or when being stored in pharmacy shops or hospitals for use by consumers.
Ergometrine [27] , nifedipine [28] , nitroprusside, riboflavin and phenothiazines are very liable to photo-oxidation. In susceptible compounds, photochemical energy creates free radical intermediates, which can perpetuate chain reactions. Most compounds will degrade as solutions when exposed to high-energy UV exposures. Fluroquinolone antibiotics are also found to be susceptible to photolytic cleavage [29] .
In ciprofloxacin eye drop preparation (0.3%), sunlight induces photocleavage reaction producing ethylenediamine analog of ciprofloxacin [30] .
Decarboxylation of some dissolved carboxylic acids, such as p-aminosalycylic acid;
shows the loss of carbon dioxide from the carboxyl group when heated. An example of decarboxylation is the photoreaction of rufloxacin [31] .
As seen earlier, impurities in drug products can come from the drug or from excipients or can be brought into the system through an inprocess step by contact with the packaging material.
For most drugs, the reactive species consist of;
• Water-that can hydrolyze some drugs or affect the dosage form performance
• Small electrophiles-like aldehydes and carboxylic acid derivatives [32] . Generally most synthetic materials contain leachable oligomers/monomers, vulcanizing agents, accelerators, plasticizers, and antioxidants [33] . Some examples of leachable/extractables from synthetic materials include styrene from polystyrene, [34] diethylhexylphalate (DEHP, plasticizer in PVC), [35] dioctyltin isooctylmercaptoacetate (stabilizer for PVC), [36] zinc stearate (stabilizer in PVC and polypropylene), [37] 2-mercaptobenzothiazole (accelerator in rubber stopper), [38] and furfural from rayon [39] .
These impurities are needed to be analyzed by using different analytical methods.
Analytical method development
New drug development requires meaningful and reliable analytical data to be produced at various stages of the development [40] [41] [42] [43] . The above three methods are briefly discussed in Table 2 .
The impurities can be identified predominantaly by following methods;
• Reference standard method
• Spectroscopic method
• Separation method
• Isolation method
• Characterization method
Reference standard method
The key objective of this is to provide clarity to the overall life cycle, qualification and governance of reference standards used in development and control of new drugs. Reference standards serve as the basis of evaluation of both process and product performance and are the benchmarks for assessment of drug safety for patient consumption. These standards are needed, not only for the active ingredients in dosage forms but also for impurities, degradation products, starting materials, process intermediates, and excipients.
Spectroscopic methods
The UV, IR, MS, NMR and Raman spectroscopic methods are routinely being used for characterizing impurities [6] .
Separation methods
The Capillary electrophoresis (CE), Chiral Separations, Gas Chromatography (GC), Supercritical Fluid Chromatography (SFC), TLC, HPTLC, HPLC are regularly being used for separation of impurities and degradation products [6] . 
Isolation methods
It is often necessary to isolate impurities. But if the instrumental methods are used, isolation of impurities is avoided as it directly characterizes the impurities.
Generally, chromatographic and non-chromatographic techniques are used for isolation of impurities prior its characterization. The term 'chromatographic reactor' refers to the use of an analytical-scale column as both a flow-through reactor, and simultaneously, as separation medium for the reactant(s) and product(s). By using an HPLC, chromatographic reactor approach, the solution-phase hydrolysis kinetics of the Aprepitant (Emend TM ) prodrug, fosaprepitant dimeglumine, were investigated [44] . In loratidine, impurity found was ofloratidine [45] , other examples include celecoxib [46] , and amikacin [47] . A list of methods that can be used for isolation of impurities is given below.
• Solid-phase extraction methods standard mixture of authentic materials containing both monomers and dimers [48] .
Unfortunately, NMR has traditionally been used as a less sensitive method compared to other analytical techniques. Conventional sample requirements for NMR are on the order of 10 mg, as compared with MS, which requires less than 1 mg.
MS
It has an increasingly significant impact on the pharmaceutical development process over and the chemical ionization of d-allethrine [49] .
The popularity of LC-MS-MS systems for complex mixture analysis of thermally labile and biologically relevant molecules, viz mosapride, is largely attributed to the "soft" nature of atmospheric pressure chemical ionization (APCI), and atmospheric pressure ionization (APPI), [50] .
HPLC-DAD-MS (HPLC coupled with a diode array UV detector and a mass spectrometer, and such other techniques are almost routinely used.
NMR has now been added to this combination to provide HPLC-DAD-NMR-MS capabilities in a commercial instrument.
In GC-MS of methamphetamine and in LC-MS of risperidone, and cetrizine tablets a number of other chromatographic and spectroscopic configurations are found to be perfectly suitable for initial characterization of the impurities [51] [52] [53] [54] .
The goal for investigation of impurities is outlined in Table 3 . A common goal for investigation of both process and product degradation-related impurities is to determine which of the many potential impurities are, in fact, produced in the manufacturing process and which occur under a given set of storage conditions.
Applications
Numerous applications have been sought in the areas of drug designing and in monitoring quality, stability, and safety of pharmaceutical compounds, whether produced synthetically, extracted from natural products or produced by recombinant methods. The applications include alkaloids, amines, amino acids, analgesics, antibacterials, anticonvulsants, antidepressant, tranquilizers, antineoplastic agents, local anesthetics, macromolecules, steroids, miscellaneous [9] . 
Conclusion
Nowadays, it is mandatory requirements in various pharmacopoeias to know the impurities present in API's.
Isolation and characterization of impurities is required for acquiring and evaluating data that establishes biological safety which reveals the need and scope of impurity profiling of drugs in pharmaceutical research. To isolate and quantify the impurities, various instrumental analytical techniques are routinely been used.
